Lurbinectedin | List of Frontiers open access articles

Review

Published on 23 Feb 2022

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives

in Pharmacology of Anti-Cancer Drugs

Lucia Musacchio
Carlo Maria Cicala
Vanda Salutari
Floriana Camarda
Maria Vittoria Carbone
Viola Ghizzoni
Elena Giudice
Camilla Nero
Maria Teresa Perri
Caterina Ricci

Frontiers in Oncology

doi 10.3389/fonc.2022.831612

4,813 views
6 citations

Review

Published on 30 Aug 2022

Lurbinectedin in small cell lung cancer

in Thoracic Oncology

Anna Manzo
Vincenzo Sforza
Guido Carillio
Giuliano Palumbo
Agnese Montanino
Claudia Sandomenico
Raffaele Costanzo
Giovanna Esposito
Francesca Laudato
Edoardo Mercadante

Frontiers in Oncology

doi 10.3389/fonc.2022.932105

19,332 views
25 citations

Systematic Review

Published on 03 Nov 2022

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma

in Pharmacology of Anti-Cancer Drugs

Angiolo Gadducci
Stefania Cosio

Frontiers in Oncology

doi 10.3389/fonc.2022.914342

10,571 views
24 citations

Original Research

Published on 15 Jun 2023

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

in Thoracic Oncology

Salvador Fudio
Laura Pérez-Ramos
Eduardo Asín-Prieto
Ali Zeaiter
Rubin Lubomirov

Frontiers in Oncology

doi 10.3389/fonc.2023.1152371

3,703 views
5 citations

Original Research

Published on 14 Mar 2024

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database

in Predictive Toxicology

Zhao Li
Changying Guo
Xingfei Liu
Zhengzhou Qiu
Ruilin Zhang

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1368763

5,327 views
7 citations

Perspective

Published on 18 Jun 2021

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases

in Gastrointestinal Cancers

Louis Gros
Petr Szturz
Antonella Diciolla
Volker Kirchner
Solange Peters
Niklaus Schaefer
Martin Hubner
Antonia Digklia

Frontiers in Oncology

doi 10.3389/fonc.2021.704295

4,530 views
1 citation

Review

Published on 01 Mar 2022

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment

in Pharmacology of Anti-Cancer Drugs

Paola Allavena
Cristina Belgiovine
Elisabeth Digifico
Roberta Frapolli
Maurizio D’Incalci

Frontiers in Oncology

doi 10.3389/fonc.2022.851790

7,693 views
32 citations

Systematic Review

Published on 31 Aug 2021

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies

in Pharmacology of Anti-Cancer Drugs

Nicholas R. Liguori
Young Lee
William Borges
Lanlan Zhou
Christopher Azzoli
Wafik S. El-Deiry

Frontiers in Pharmacology

doi 10.3389/fphar.2021.747180

7,739 views
13 citations

Original Research

Published on 23 Sep 2025

Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer

in Cancer Immunity and Immunotherapy

Yufan Huang
Zheqi Xu
Leilei Bao

Frontiers in Immunology

doi 10.3389/fimmu.2025.1658740

3,300 views

Original Research

Published on 22 Aug 2023

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity

in Cancer Immunity and Immunotherapy

Adrián Povo-Retana
Marco Fariñas
Rodrigo Landauro-Vera
Marina Mojena
Carlota Alvarez-Lucena
Miguel A. Fernández-Moreno
Antonio Castrillo
Juan Vladimir de la Rosa Medina
Sergio Sánchez-García
Carles Foguet

Frontiers in Immunology

doi 10.3389/fimmu.2023.1211068

6,190 views
12 citations

Review

Published on 08 Sep 2022

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

in Pharmacology of Anti-Cancer Drugs

Rita De Sanctis
Flavia Jacobs
Chiara Benvenuti
Mariangela Gaudio
Raul Franceschini
Richard Tancredi
Paolo Pedrazzoli
Armando Santoro
Alberto Zambelli

Frontiers in Pharmacology

doi 10.3389/fphar.2022.909566

7,623 views
11 citations

Clinical Trial

Published on 31 Jul 2024

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer

in Thoracic Oncology

Margaret M. Byrne
Grerk Sutamtewagul
William Zeitler
Sarah L. Mott
Gideon K.D. Zamba
Arsenije Kojadinovic
Jun Zhang
Taher Abu-Hejleh
Gerald Clamon
Muhammad Furqan

Frontiers in Oncology

doi 10.3389/fonc.2024.1303268

3,069 views
1 citation

Articles

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives

Lurbinectedin in small cell lung cancer

Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma

A model-based head-to-head comparison of single-agent lurbinectedin in the pivotal ATLANTIS Study

Post-marketing safety evaluation of lurbinectedin: a pharmacovigilance analysis based on the FAERS database

Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases

Effects of the Anti-Tumor Agents Trabectedin and Lurbinectedin on Immune Cells of the Tumor Microenvironment

Absence of Biomarker-Driven Treatment Options in Small Cell Lung Cancer, and Selected Preclinical Candidates for Next Generation Combination Therapies

Cost-effectiveness analysis of lurbinectedin plus atezolizumab as first-line treatment for extensive-stage small-cell lung cancer

Immunometabolic actions of trabectedin and lurbinectedin on human macrophages: relevance for their anti-tumor activity

From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds

Phase II study of nab-paclitaxel with gemcitabine for relapsed/refractory small cell lung cancer